|
2021 Journal Article A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphomaTobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866 |
|
2020 Journal Article Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environmentKobayashi, Takumi, Lam, Pui Yeng, Jiang, Hui, Bednarska, Karolina, Gloury, Renee Elyse, Murigneux, Valentine, Tay, Joshua, Jacquelot, Nicolas, Li, Rui, Tuong, Zewen Kelvin, Leggatt, Graham, Gandhi, Maher K., Hill, Michelle M, Belz, Gabrielle T., Ngo, Shyuan, Kallies, Axel and Mattarollo, Stephen R. (2020). Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 136 (26), 3004-3017. doi: 10.1182/blood.2020005602 |
|
2020 Conference Publication Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphomaTsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954 |
|
2020 Conference Publication A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphomaTobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590 |
|
2020 Journal Article DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?Hertzberg, Mark, Joske, David J. L. and Gandhi, Maher K. (2020). DA-EPOCH-R in Burkitt Lymphoma: Is it enough for high-risk disease?. Journal of Clinical Oncology, 38 (31), 3722-3723. doi: 10.1200/jco.20.01850 |
|
2020 Journal Article Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphomaGunawardana, Jay, Lee, Justina N., Bednarska, Karolina, Murigneux, Valentine, Long, Lilia Merida, Sabdia, Muhammed B., Birch, Simone, Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma. eJHaem, 1 (2) jha2.116, 517-526. doi: 10.1002/jha2.116 |
|
2020 Journal Article Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?Tobin, Joshua W. D. and Gandhi, Maher K. (2020). Risk‐adapted therapy in follicular lymphoma: is it time to FLEX ?. American Journal of Hematology, 95 (12) ajh.26016, 1454-1456. doi: 10.1002/ajh.26016 |
|
2020 Journal Article Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphomaBararia, Deepak, Hildebrand, Johannes A., Stolz, Sebastian, Haebe, Sarah, Alig, Stefan, Trevisani, Christopher P., Osorio-Barrios, Francisco, Bartoschek, Michael D., Mentz, Michael, Pastore, Alessandro, Gaitzsch, Erik, Heide, Michael, Jurinovic, Vindi, Rautter, Katharina, Gunawardana, Jay, Sabdia, Muhammed B., Szczepanowski, Monika, Richter, Julia, Klapper, Wolfram, Louissaint, Abner, Ludwig, Christina, Bultmann, Sebastian, Leonhardt, Heinrich, Eustermann, Sebastian, Hopfner, Karl-Peter, Hiddemann, Wolfgang, von Bergwelt-Baildon, Michael, Steidl, Christian, Kridel, Robert ... Weigert, Oliver (2020). Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma. Cell Reports, 31 (5) 107522, 107522. doi: 10.1016/j.celrep.2020.107522 |
|
2020 Journal Article LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphomaKeane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark and Gandhi, Maher K. (2020). LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 4 (7), 1367-1377. doi: 10.1182/bloodadvances.2019001390 |
|
2020 Journal Article Reply to M. SorigueTobin, Joshua W.D., Keane, Colm, Gunawardana, Jay and Gandhi, Maher K. (2020). Reply to M. Sorigue. Journal of Clinical Oncology, 38 (6), 648-649. doi: 10.1200/JCO.19.02935 |
|
2020 Journal Article Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibodyNakamura, Kyohei, Casey, Mika, Oey, Harald, Vari, Frank, Stagg, John, Gandhi, Maher K. and Smyth, Mark J. (2020). Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 34 (10), 2708-2721. doi: 10.1038/s41375-020-0811-3 |
|
2019 Conference Publication Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockadeNath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050 |
|
2019 Journal Article EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2Cristino, Alexandre S., Nourse, Jamie, West, Rachael A., Sabdia, Muhammed Bilal, Law, Soi C., Gunawardana, Jay, Vari, Frank, Mujaj, Sally, Thillaiyampalam, Gayathri, Snell, Cameron, Gough, Madeline, Keane, Colm and Gandhi, Maher K. (2019). EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2. Blood, 134 (25), 2261-2270. doi: 10.1182/blood.2019000889 |
|
2019 Journal Article Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceTobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458 |
|
2019 Journal Article The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphomaKeane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274 |
|
2019 Journal Article Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltrationTobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365 |
|
2019 Journal Article COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyBarraclough, Allison, Alzahrani, Musa, Ettrup, Marianne Schmidt, Bishton, Mark, van Vliet, Chris, Farinha, Pedro, Gould, Clare, Birch, Simone, Sehn, Laurie H., Sovani, Vishakha, Ward, Mitchell Steven, Augustson, Bradley, Biccler, Jorne, Connors, Joseph M., Scott, David W., Gandhi, Maher K., Savage, Kerry J., El-Galaly, Tarec, Villa, Diego and Cheah, Chan Yoon (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 3 (13), 2013-2021. doi: 10.1182/bloodadvances.2019000251 |
|
2019 Journal Article Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functionsStannard, Kimberley A., Lemoine, Sébastien, Waterhouse, Nigel J., Vari, Frank, Chatenoud, Lucienne, Gandhi, Maher K., Martinet, Ludovic, Smyth, Mark J. and Guillerey, Camille (2019). Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 3 (11), 1681-1694. doi: 10.1182/bloodadvances.2018030676 |
|
2019 Conference Publication EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapyGandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629 |
|
2019 Journal Article Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directionsLees, Charlotte, Keane, Colm, Gandhi, Maher K. and Gunawardana, Jay (2019). Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. British Journal of Haematology, 185 (1), 25-41. doi: 10.1111/bjh.15778 |
